Comments
Pharma major Dr Reddy’s Laboratories Ltd has launched abiraterone acetate tablets, a therapeutic equivalent generic version of Zytiga, in the US market.
The drug has been approved by the US Food and Drug Administration (USFDA).
Zytiga is a trademark of Johnson & Johnson Corporation. The Zytiga brand and generic market had US sales of approximately $454 million for the 12 months ended March 2020, according to IQVIA Health.
Hyderabad-based Dr Reddy’s abiraterone acetate is available in 250 mg tablets in bottle count sizes of 120, according to a release.
Abiraterone acetate tablets are a CYP17 inhibitor indicated in combination with rednisone for the treatment of patients with metastatic castration-resistant prostate cancer.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.